Perfluorooctanoate (PFOA) and perfluorooctane sulfonate (PFOS) are persistent environmental contaminants that affect metabolic regulation, inflammation, and other factors implicated in the pathogenesis of osteoarthritis (OA). However, the link between these compounds and OA remains unknown. In this study, the authors investigated the association of OA with PFOA and PFOS in a population of 49,432 adults from 6 PFOA-contaminated water districts in the mid-Ohio Valley (2005)(2006). Participants completed a comprehensive health survey; serum levels of PFOA, PFOS, and a range of other blood markers were also measured. Medical history, including physician diagnosis of osteoarthritis, was assessed via self-report. Analyses included adjustment for demographic and lifestyle characteristics, body mass index, and other potential confounders. Reported OA showed a significant positive association with PFOA serum levels (for highest quartile of PFOA vs. lowest, adjusted odds ratio ¼ 1.3, 95% confidence interval: 1.2, 1.5; P-trend ¼ 0.00001) and a significant inverse association with PFOS (for highest quartile vs. lowest, adjusted odds ratio ¼ 0.8, 95% confidence interval: 0.7, 0.9; P-trend ¼ 0.00005). The relation between PFOA and OA was significantly stronger in younger and nonobese adults. Although the cross-sectional nature of this large, population-based study limits causal inference, the observed strong, divergent associations of reported OA with PFOA and PFOS may have important public health and etiologic implications and warrant further investigation.
Osteoarthritis is the most common degenerative joint disease, characterized by joint pain, stiffness, and physical dysfunction and accompanied by synovial inflammation, progressive loss of articular cartilage, and associated changes in adjacent subchondrial bone (1, 2) . Because osteoarthritis symptoms are insidious in onset and often do not correlate well with radiographic abnormalities, diagnosis is generally based on clinical symptoms (1, 3) . Osteoarthritis affects at least 27 million Americans over age 25 years (4) and is associated with dramatic reductions in quality of life (2, (5) (6) (7) , significant comorbidity (6) , increased mortality (8) , and substantial economic and health-care burden (2, 5) . However, progress in the prevention and treatment of this debilitating disorder has been slow, probably partly because of the still-incomplete understanding of the mechanisms underlying osteoarthritis etiology and progression (6, 9) .
Established risk factors for osteoarthritis include age; female gender; obesity; joint malformations, instability, and hypermobility; physical trauma; history of joint immobilization; and genetic predisposition (1, 2, 5, 6, 10). Elevations in uric acid level (11) and oxidative stress (12) , proinflammatory changes (12) (13) (14) and other adverse alterations in the immune system (15, 16) , and metabolic perturbations (17) (18) (19) have also been implicated in osteoarthritis pathogenesis. In addition, a recent study documented links between osteoarthritis and exposure to persistent organic pollutants, including polychlorinated biphenyls, in women, although the numbers were small (116 cases of osteoarthritis) (20) . However, while a number of environmental pollutants are known to have adverse health effects in humans (21, 22) , the link between chemical exposures and osteoarthritis remains little investigated.
Perfluoroalkyl acids (PFAAs) such as perfluorooctanoate (PFOA) and perfluorooctane sulfonate (PFOS) are exclusively man-made chemicals that are widely used to manufacture popular consumer products used in the nonstick and stain-resistant coatings of cookware, food containers, furniture, and carpets. PFAAs feature strong carbon-fluorine bonds, resist environmental degradation, and have become widespread, persistent environmental pollutants (22) . PFOS and PFOA have been repeatedly documented in sera from a broad range of human populations in both developed and developing countries (23) (24) (25) . Human half-lives of these compounds are long. For example, in a study of retired American fluorochemical production workers, Olsen et al. (26) estimated the average half-lives of PFOS and PFOA to be 5.4 years and 3.8 years, respectively; other recent studies of PFOA-exposed populations in Germany (27) and the United States (28) have yielded somewhat lower PFOA half-life estimates of 3.3 years and 2.3 years, respectively. PFOS and PFOA have been shown to have adverse effects on liver and thyroid function in experimental models (21, 22, 29) and have recently been linked to thyroid disease (30) and elevated levels of liver enzymes (31) in humans. These compounds have also been associated with elevations in serum uric acid levels (32) , adverse lipid profiles (33) (34) (35) (36) , and insulin resistance (35) in humans, shown to cause marked immunomodulation in animals (21) and increased oxidative stress in human cell systems (29, 37) , and linked to both proand antiinflammatory changes in both humans and experimental models (21, 38) . Many of these factors have been linked to osteoarthritis risk and implicated in osteoarthritis pathogenesis (11, 12, 14, 15, 19, 39) .
In this study, we investigated the association of osteoarthritis with PFOA and PFOS in a large, community-based study of adults from 6 PFOA-contaminated water districts in 2 states who were exposed to elevated PFOA levels through contaminated drinking water. On the basis of the existing literature regarding osteoarthritis risk and the effects of PFAAs, we hypothesized that both PFOA and PFOS would be significantly linked, in the same direction, to the likelihood of osteoarthritis.
MATERIALS AND METHODS

Study population
Subjects were drawn from participants in the C8 Health Project (32, 40) , which arose from the settlement of a classaction lawsuit related to widespread PFOA contamination of drinking water by a chemical plant in Washington, West Virginia. Baseline data on 69,030 persons living or working in 6 PFOA-contaminated water districts in Ohio and West Virginia (including those exposed to contaminated privatewell drinking water) were collected from August 2005 to August 2006. Project details, from consent and enrollment to data collection, cleaning, and reporting, have been published elsewhere (40) and are described online (http://www. hsc.wvu.edu/som/cmed/c8/). Participant consent was obtained using a process approved by parties to the settlement that included language specific to the project's purpose and data collection procedures (36, 40) . The West Virginia University C8 Project Group obtained institutional review board approval permitting access to the deidentified project data for purposes of analysis and publication.
Among adult residents of the affected water districts, the estimated rate of participation in the C8 Health Project was 81% (32) . For the current study, eligible participants included all adults aged 21 years at the time of baseline assessment; those who had received a diagnosis of rheumatoid arthritis (n ¼ 2,002) were excluded from the analyses, leaving a total of 51,426 eligible adults. Exclusion of persons with missing data on PFOA and PFOS (n ¼ 333; 0.65%) and other covariates of interest (n ¼ 1,661; 3.23%) yielded a final study sample of 49,432, including 45,701 arthritis-free controls and 3,731 adults with osteoarthritis (see Figure 1 ). Relative to participants included in the analyses, those with missing data on any covariate were more likely to have higher serum levels of PFOA; to be female and postmenopausal; to be older, less educated, and heavier; and to report a lower income and higher prevalence of osteoarthritis and comorbid medical conditions (P < 0.01).
Outcome and exposure measurements
The C8 Health Project included a comprehensive health survey, clinical blood tests, and determination of serum levels of PFOA, PFOS, and 8 other perfluorocarbons (40) . Project data collection was administered by Brookmar, Inc. (Parkersburg, West Virginia) and conducted under the authority and supervision of the Wood County, West Virginia, Circuit Court (36, 40) .
Medical history, including physician diagnosis of osteoarthritis and other medical conditions, was assessed via self-report questionnaires. Diagnoses of certain disorders, including cancer, diabetes, and cardiovascular disease, were further verified via chart review. While self-reported diagnosis of osteoarthritis was not externally verified, a previous validation study demonstrated over 80% agreement between self-reported and clinically confirmed diagnoses of osteoarthritis (41) , comparable to the 74% concordance observed between self-reports and medical record-verified data on another common chronic disorder (diabetes) in the C8 Health Project population (42) . Demographic, lifestyle, and anthropometric characteristics were also determined via self-report; demographic data and health survey completion were verified by trained project staff.
Laboratory methods: determination of PFOA and PFOS levels Blood processing and analytical methods, along with quality-assurance measures, have previously been described in detail (32, 34, 40) . Briefly, following collection of each blood sample, serum was separated from red blood cells, refrigerated, and transported on dry ice to the laboratory for analysis. The PFAA detection method used protein precipitation extraction with reverse-phase high-performance liquid chromatography/tandem mass spectrometry. Detection was performed using a triple quadrupole mass spectrometer in selected reaction monitoring mode, monitoring for the M/Z transitions of 10 individual perfluorocarbon compounds and a 13 C-PFOA surrogate. Results were automatically transferred into the project's Windows-based information system (Microsoft, Inc., Seattle, Washington).
Statistical analysis
Data were analyzed using SPSS, version 18 (SPSS, Inc., Chicago, Illinois). We used logistic regression analysis to evaluate the associations of PFOA and PFOS serum levels and other factors with diagnosis of osteoarthritis, to assess the influence of potential confounders, and to evaluate potential effect modifiers; linear trends were assessed using polynomial contrasts. Potential differences between participants with and without missing data were evaluated using Student's t test or the Mann-Whitney U test for continuous or ordinal variables and the chi-squared test for categorical variables. The primary explanatory variables of interest, PFOA and PFOS, were analyzed as both categorical (study population quartiles and ventiles, with the lowest percentile group used as the referent category) and continuous (logtransformed) variables. All P values presented are 2-sided.
Factors on which adequate data were available and which have been previously linked to osteoarthritis and/or the 2 PFAAs of interest were selected a priori as covariates. Associations of PFAAs with osteoarthritis were initially adjusted for age and body mass index, factors strongly correlated with PFOA and PFOS and predictive of osteoarthritis. Unless stated otherwise, all other multivariable models included adjustment for age, gender, race/ethnicity, marital status, socioeconomic status (including years of education, average family income, and employment status/disability), participation in a regular exercise program (yes/no), vegetarian diet (yes/no), smoking (never, former, or current smoker), current alcohol consumption (yes/no), menopausal status and use of hormone replacement therapy (for women), body mass index (calculated as weight (kg)/height (m) 2 ), medical comorbidity (reported physician diagnosis of other medical conditions, including heart, kidney, liver, thyroid, immune, and connective tissue disease, stroke, hypertension, dyslipidemia, fibromyalgia, diabetes, chronic obstructive pulmonary disease, or asthma), and current treatment for hypertension or hyperlipidemia. Additional analyses adjusted for serum levels of uric acid (mg/dL), cholesterol (mg/dL), C-reactive protein (mg/L), estradiol (pg/mL), and other PFAAs measured in the C8 Health Project; military service and associated exposures to harmful chemicals; and reports of sleep impairment, frequent recent memory loss, and frequent mood swings.
To evaluate potential modifying effects of gender, age, and obesity on the association between PFAA levels (in quartiles) and history of osteoarthritis, we conducted multivariable analyses stratified by each potential effect modifier. We tested the strength of each interaction by including the corresponding multiplicative interaction term in the main adjusted statistical model and evaluating the coefficient using the Wald test. Table 1 illustrates the distribution of study population characteristics by osteoarthritis diagnosis. Participants were predominantly non-Hispanic white, ranging in age from 21 years to 105 years (mean age ¼ 46.4 years; standard deviation, 15.3). Fifty-two percent were female, 53% had received only 12 years of schooling or less, and 37% reported an annual household income of less than $30,000. Sixty-two percent were employed, and approximately 6% were disabled. Over 70% of the adults in this population were overweight (body mass index 25), and over 35% were obese (body mass index 30).
RESULTS
Of the 49,432 eligible participants with no missing data, 3,731 reported receiving a diagnosis of osteoarthritis from a physician, yielding a crude population prevalence of 7.6% (95% confidence interval (CI): 7.3, 7.8). Reported prevalence increased strongly with age, ranging from 0.5% in adults aged 21-30 years to 23.4% in adults aged 70 years or older, and was significantly higher in women than in men (10.1% vs. 4.8%; P < 0.00001) ( Table 1) . After adjustment for all other factors in the table, reported osteoarthritis retained significant, positive associations with body mass index, postmenopausal status, and history of hormone replacement therapy and significant negative associations with educational level, household income, and black race/ethnicity. Participants who were retired or homemakers, who were disabled, who had been diagnosed with at least 1 chronic medical condition, or who were receiving treatment for hypertension or hyperlipidemia were also significantly more likely to report a diagnosis of osteoarthritis (adjusted P < 0.0001).
Serum PFOA values were high overall in this population, averaging 87.4 ng/mL (standard deviation, 268.7; median, 28.2; range, <0.5-22,412 ng/mL). In contrast, PFOS blood values were similar to those in the general US population (32), ranging from <0.5 ng/mL to 729.2 ng/mL and averaging 23.5 ng/mL (standard deviation, 16.2; median, 20.3 ng/mL). Similarly, serum levels of other PFAAs were similar to general US background levels. Table 2 illustrates the associations between history of osteoarthritis and serum levels of PFOA and PFOS. PFOA showed a modest but significant positive relation with osteoarthritis in both the minimally adjusted analysis and the full models. Persons testing in the highest quartile of PFOA were 20% more likely to report a diagnosis of osteoarthritis than those testing in the lowest quartile (odds ratio ¼ 1.2, 95% confidence interval (CI): 1.1, 1.3; P-trend ¼ 0.0002) after adjustment for age and body mass index. Further adjustment for gender, ethnicity, education, household income, menopausal status and use of hormone replacement therapy (for women), lifestyle factors, and comorbidity strengthened this association (for the second, third, and highest quartiles of PFOA, odds ratios were 1.1 (95% CI: 1.0, 1.2); 1.1 (95% CI: 1.0, 1.3), and 1.3 (95% CI: 1.2, 1.5), respectively; P-trend ¼ 0.00001). Additional adjustment for military service and associated chemical exposures, recent memory loss, mood and sleep impairment, and serum levels of estradiol, cholesterol, uric acid, and C-reactive protein further strengthened this positive linear relation (for the highest quartile vs. the lowest, odds ratio ¼ 1.4, 95% CI: 1.3, 1.6; P-trend ¼ 0.00001). The association of osteoarthritis with serum PFOA analyzed as a continuous variable showed a similar pattern, with the strength of the linear relation increasing following adjustment for other demographic, lifestyle, and health-related factors (Table 2) . Further adjustment for other PFAAs did not materially alter these risk estimates.
PFOS was also significantly related to reported diagnosis of osteoarthritis, but in the opposite direction (Table 2) . After adjustment for age and body mass index, PFOS showed a strong, negative association with reported osteoarthritis, with persons in the highest PFOS quartile showing an approximately 30% reduced probability of reporting osteoarthritis relative to those in the lowest quartile (odds ratio ¼ 0.7, 95% CI: 0.6, 0.8; P-trend < 0.00001). Additional adjustment for other demographic, socioeconomic, lifestyle, and healthrelated factors slightly attenuated this protective association, although the linear trend remained highly significant (P < 0.0001).
As detailed in Table 3 , the association between PFOA and osteoarthritis was more pronounced, with a stronger linear trend in adults under 55 years of age than in those aged 55 years or older (for the highest quartile vs. the lowest, adjusted odds ratios were 1.5 (95% CI: 1.3, 1.8) and 1.1 (95% CI: 1.0, 1.3), respectively; P-interaction < 0.00001). The relation of PFOA also appeared stronger in nonobese adults (body mass index <30) than in obese adults (body mass index 30) (for the highest quartile vs. the lowest, adjusted odds ratios were 1.4 (95% CI: 1.2, 1.6) and 1.1 (95% CI: 0.9, 1.4), respectively; P-interaction ¼ 0.0005). In contrast, we did not find evidence of a modifying effect of age or body mass index on the relation of osteoarthritis to PFOS.
Sensitivity analyses
To ensure that the observed positive relation of PFOA to osteoarthritis was not driven by adults with extremely high PFOA levels, we restricted our analyses to adults with PFOA levels below the 90th percentile (<193 ng/mL). Eliminating the top percentile did not appreciably alter the observed linear association (adjusted odds ratios for the second, third, and fourth quartiles of PFOA were 1.1 (95% CI: 1.0, 1.2), 1.2 (95% CI: 1.0, 1.3), and 1.3 (95% CI: 1.2, 1.5), respectively; P-trend < 0.00001). To determine whether the observed positive association between PFOA and osteoarthritis was evident at exposure levels more typical of noncontaminated areas, we also restricted our analyses to adults with serum PFOA concentrations less than or equal to 20 ng/mL (n ¼ 17,885 adults, including 1,167 with osteoarthritis), with the lowest quartile (referent group) comprising blood levels similar to those in the US general population (32) . Restricting the analysis to adults with these relatively low levels of exposure did not alter the inverse relation of PFOS to osteoarthritis, but it largely eliminated the association of PFOA with osteoarthritis, suggesting that the observed increase in osteoarthritis risk associated with elevated PFOA levels may represent a threshold effect that is more consistently apparent at higher serum concentrations. As indicated in Figure 2 , the likelihood of a reported osteoarthritis diagnosis rose with increasing PFOA serum percentile overall, relative to the lowest percentile range (5th percentile, 5.8 ng/mL), appearing to level off between the 75th and 80th percentiles (PFOA levels 72.0 ng/mL), with the largest and most consistent elevations being seen in the upper quartile. Using the contemporaneous US population mean for PFOA (National Health and Nutrition Examination Survey, 2003-2004 (23) ) as the referent category yielded similar results. In contrast, the probability of osteoarthritis diagnosis declined with increasing PFOS serum percentile, with no apparent leveling off in the upper quartile range (Figure 2 ).
DISCUSSION
Our findings indicate a significant positive, linear association between PFOA and osteoarthritis in this large crosssectional study. In contrast to our hypothesis that PFOS would show a similar relation to osteoarthritis, our findings indicate a significant negative association between PFOS and a reported diagnosis of osteoarthritis. After adjustment for multiple potential confounders, persons with serum PFOA levels in the highest quartile were approximately 40% more likely to report a diagnosis of osteoarthritis; conversely, those in the highest quartile of PFOS were approximately 25% less likely to report osteoarthritis. The observed relation between PFOA and osteoarthritis was significantly stronger in adults under 55 years of age and in nonobese adults. The positive association of PFOA with osteoarthritis also appeared evident only at serum concentrations above the mean of the US general population, suggesting a possible threshold effect.
To our knowledge, this is the first study to examine the potential links between osteoarthritis and environmental PFAAs. While the observed elevation in risk associated with PFOA levels was modest, it is nonetheless potentially of considerable public health importance, given the high prevalence of osteoarthritis and the significant economic, social, and health-care costs associated with this disorder. Although causality cannot be determined because of the cross-sectional nature of the data, the robust associations of both PFOA and PFOS with osteoarthritis in younger adults, who are likely to have been diagnosed more recently, coupled with the long half-life of these perfluorocarbons, suggest the possibility that a causal relation may be present.
This study is among the first to document a link between these environmental pollutants and a specific chronic disorder in humans. Although prior research in this population has shown cholesterol (34, 36) and uric acid (32) to have significant positive associations with both PFAAs, the association of osteoarthritis with PFOA differed markedly from that with PFOS in this study. While we found a strong, positive relation between PFOA and reported osteoarthritis, elevated PFOS levels were associated with a reduced likelihood of osteoarthritis diagnosis. These divergent associations remained after adjustment for multiple potential confounders, suggesting that the 2 PFAAs may be affecting osteoarthritis in different ways and perhaps via different mechanisms. In addition, while previous studies in this cohort showed the linear association of cholesterol and uric acid with these 2 PFAAs to decline in strength with increasing exposure levels, demonstrating the strongest linear associations in the first quartile (32, 34) , the associations of osteoarthritis with PFOA (positive) and PFOS (negative) remained relatively robust throughout the range of exposure levels in this study. As indicated above, the positive relation of PFOA to osteoarthritis appears, in fact, to be considerably stronger in the upper quartile ranges and to plateau only at serum concentrations well above those found in the general population.
Consistent with previous research (2, 6, 43) , female gender, obesity, advancing age, lower educational level, poverty, and chronic comorbid conditions were significantly associated with reported osteoarthritis in this study. The elevated prevalence of osteoarthritis in women who reported use of hormone replacement therapy also parallels findings . c Smoking (never, former, or current smoker), current alcohol consumption (yes/no), vegetarian diet (yes/no), exercise (regular exercise program (yes/no)), and socioeconomic status (including years of education, annual household income, and employment status/disability).
d Comorbidity includes physician diagnosis of comorbid conditions (heart, kidney, liver, immune, connective tissue, or thyroid disease; stroke; hypertension; dyslipidemia; fibromyalgia; diabetes; chronic obstructive pulmonary disease; or asthma) and current treatment for hypertension or hyperlipidemia.
e Report of sleep impairment, frequent mood disturbance, or frequent recent memory loss. f All P values are 2-sided.
of some (44-47) (although not all (48, 49) ) previous studies of both clinically determined (45) and self-reported (46, 47) osteoarthritis, including recently published findings from the Women's Health Initiative (46) . In contrast to most previous studies (2), African-American adults were less likely to report a diagnosis of osteoarthritis in this population relative to non-Hispanic white adults, an association that persisted after adjustment for other known risk factors.
Strengths and limitations
The strengths of the study include the large sample size, the population-based design, and the high study participation rates in an Appalachian region. Additional strengths include our ability to evaluate persistent biomarkers of PFAA exposure obtained concurrently with survey information regarding diagnosis of osteoarthritis and other conditions, the measurement of a broad array of biomarkers, and the extensive information available on potential confounders and effect modifiers. We were also able to assess the association of osteoarthritis with PFOA and PFOS over a wide range of serum concentrations, helping to clarify the possible modifying effects of exposure level.
Our study had a number of limitations as well. The crosssectional nature of the data limited our ability to determine the direction of causality. We lacked information on certain risk factors for osteoarthritis, including history of physical trauma and strain. Ascertainment of osteoarthritis was based on participant-reported physician diagnosis and was not confirmed by chart review. Although at least 1 previous clinical validation study has shown self-reporting of general osteoarthritis to be reliable (41) , consistent with the agreement between self-report and medical record-verified data on another common disorder, diabetes, in this study population (42), the accuracy of using self-reported diagnoses of osteoarthritis to estimate osteoarthritis prevalence is unknown. Moreover, the estimated crude osteoarthritis prevalence of 7.6% in this study was considerably lower than recent prevalence estimates from the Third National Health and Nutrition Examination Survey data (18, 50) , suggesting that osteoarthritis may have been underreported in this study. However, such underascertainment would be expected to bias the observed associations toward the null, and thus is unlikely to explain our findings. Exclusion of eligible participants with missing data on covariates may have introduced selection bias. However, the percentage with missing data was small (3.8%); moreover, given that persons with missing data had higher PFOA levels and were at greater risk for osteoarthritis, their exclusion would again be expected to attenuate the observed associations. Unmeasured confounding might also help explain our findings, although our ability to control for a large number of both known and potential risk factors for osteoarthritis renders this possibility less probable.
Possible underlying mechanisms
The mechanisms by which PFOA and PFOS may influence the etiology and progression of osteoarthritis are unknown. If the association with either PFAA indeed proves causal, possible physiologic explanations may include immune modulation, increased oxidative stress, elevations in uric acid, and alterations in lipid metabolism-factors which have been associated with PFOA and PFOS (21, 29, 32, 34, 36) and implicated in osteoarthritis pathophysiology (11, 12, 14, 15, 19, 39) . Both PFOA and PFOS may influence cartilage remodeling, possibly via opposing effects on inflammatory responses. Elevations in levels of interleukin-1, tumor necrosis factor alpha, and other proinflammatory cytokines are thought to play an important role in promoting both joint inflammation and cartilage degradation in osteoarthritis (12, 51) . PFOA exposure has been shown to promote cytokine release in animals (21, 38) and to augment cellular inflammatory responses in humans (21) . While PFOS has also been associated with proinflammatory effects (21, 29) , it can act as an antiinflammatory agent as well; for example, a recent study in a mouse model showed dietary exposure to PFOS to reduce serum levels of tumor necrosis factor alpha in response to an immune challenge, while PFOA increased cytokine production (38) .
This antiinflammatory action may be mediated by activation of peroxisome proliferator-activated receptors (PPARs). PPARs are transcription factors that belong to the superfamily of nuclear receptors whose natural activating ligands are lipid-derived substrates. A growing body of experimental evidence suggests that PFOA and PFOS are potent PPAR ligands, acting as agonists for both the alpha isotype (PPAR-a) and, to a lesser extent, the gamma isotype (PPAR-c) (21, 52) . PPARs are expressed in kidney, adipose, skeletal muscle, liver, and other tissues and play a major role in the regulation of glucose homeostasis, lipid metabolism, and inflammatory responses (21, 53) . PPARs are also expressed on macrophages and bone cells, including osteoblasts, osteocytes, and chondrocytes (54) . PPAR-a reduces inflammation and oxidative stress in both the vascular wall and the liver (55, 56) , and experimental evidence suggests that PPAR-c can inhibit major inflammatory signaling pathways as well as decrease synthesis of cartilage catabolic factors responsible for degradation of articular cartilage in osteoarthritis (57) . Although the literature remains inconsistent regarding the direction of effect, PPAR ligands have also been shown to significantly alter bone metabolism (54) , which in turn is considered critical in osteoarthritis pathogenesis (58) . However, whether PFOS and PFOA differentially activate PPARs involved in altered bone turnover or in inflammatory pathways associated with osteoarthritis is unknown.
Conclusions
In this cross-sectional study of a large Appalachian population, we found a significant positive, linear association between PFOA and reported diagnosis of osteoarthritis and a significant negative association between PFOS and osteoarthritis. If replicated in prospective studies, these findings could have substantial public health implications and may inform future studies regarding possible mechanisms underlying the development and progression of this important and common chronic disorder. 5th  10th  15th  20th  25th  30th  35th  40th  45th  50th  55th  60th  65th  70th  75th  80th  85th  90th  95th  >95th Odds Ratio 
